Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia
Open Access
- 27 October 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (20), 5165-5173
- https://doi.org/10.1182/bloodadvances.2019001307
Abstract
Recent genetic studies using high-throughput sequencing have disclosed genetic alterations in B-cell precursor acute lymphoblastic leukemia (B-ALL). However, their effects on clinical outcomes have not been fully investigated. To address this, we comprehensively examined genetic alterations and their prognostic impact in a large series of pediatric B-ALL cases. We performed targeted capture sequencing in a total of 1003 pediatric patients with B-ALL from 2 Japanese cohorts. Transcriptome sequencing (n = 116) and/or array-based gene expression analysis (n = 120) were also performed in 203 (84%) of 243 patients who were not categorized into any disease subgroup by panel sequencing or routine reverse transcription polymerase chain reaction analysis for major fusions in B-ALL. Our panel sequencing identified novel recurrent mutations in 2 genes (CCND3 and CIC), and both had positive correlations with ETV6-RUNX1 and hypodiploid ALL, respectively. In addition, positive correlations were also newly reported between TCF3-PBX1 ALL with PHF6 mutations. In multivariate Cox proportional hazards regression models for overall survival, TP53 mutation/deletion, hypodiploid, and MEF2D fusions were selected in both cohorts. For TP53 mutations, the negative effect on overall survival was confirmed in an independent external cohort (n = 466). TP53 mutation was frequently found in IGH-DUX4 (5 of 57 [9%]) ALL, with 4 cases having 17p LOH and negatively affecting overall survival therein, whereas TP53 mutation was not associated with poor outcomes among NCI (National Cancer Institute) standard risk (SR) patients. A conventional treatment approach might be enough, and further treatment intensification might not be necessary, for patients with TP53 mutations if they are categorized into NCI SR.This publication has 35 references indexed in Scilit:
- An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing dataNucleic Acids Research, 2013
- The genomic landscape of hypodiploid acute lymphoblastic leukemiaNature Genetics, 2013
- Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomicsNature, 2012
- Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group StudyBlood, 2012
- Mutations and Deletions of the TP53 Gene Predict Nonresponse to Treatment and Poor Outcome in First Relapse of Childhood Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2011
- Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithmNature Protocols, 2009
- Flow Cytometric DNA index, G-band Karyotyping, and Comparative Genomic Hybridization in Detection of High Hyperdiploidy in Childhood Acute Lymphoblastic LeukemiaJournal of Pediatric Hematology/Oncology, 2006
- Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 2004
- Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysisProceedings of the National Academy of Sciences of the United States of America, 2003
- Amino Acid Sequences Common to Rapidly Degraded Proteins: The PEST HypothesisScience, 1986